Start of the project: now End of the project: 31 October 2022 SHORT-TERM SCIENTIFIC MISSIONS (STSM) We offer short-term scientific mission grants to Ukrainian researchers who have been recently displaced by the war, or those who can travel to institutions participating in ERNEST COST Action. Our scientific perspective is broad, and we are happy to consider any research proposals from those in

Discovery Biology, will provide a business update and review its pipeline during a teleconference and webcast

➡️ https://www.ecosystem.drgpcr.com/ #gpcr #drgpcr

The sheer complexity of the cell and the astonishing diversity of diseases are just two reasons why researchers Drugs that do make it to clinical trials have major hurdles to clear—not the least of which is safety

launch of Phase 2 clinical development Metabolic disorders are a global epidemic1 MONTREAL--(BUSINESS WIRE Favorable safety, tolerability and pharmacokinetic results from the trial warrant further investigation

If only Voltaire were here today to see how drug discovery is being accelerated by new technologies.

2022 "GPCRs in Medicinal Chemistry Event 8th RSC / SCI symposium on GPCRs in Medicinal Chemistry Dates Wednesday-Friday

gut there is emerging interest in defining if agonists of GPR84 might find utility in conditions in which Here, we consider the physiological and pathological expression profile of GPR84 and, in the absence

Accordingly, within the erythroid lineage ACKR1 expression occurs first and is the highest in erythroblasts This well-established, distinctive pattern of cell expression has been directly challenged by a publication provocative, as this was the first description of ACKR1 expression by any leukocyte type and, if correct, would ACKR1 expression by macrophages in Hur et al. relied on using commercial anti-ACKR1 antibody FAB6695, which

closed an oversubscribed $33 million financing round, extending its $100 million Series B financing, which

disorders and cancer, today announced that the companies have entered into a definitive agreement under which

Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia "BOSTON--(BUSINESS WIRE Syndrome Scale (PANSS) total score compared to placebo (-21.2 KarXT vs. -11.6 placebo, p<0.0001) at Week sustained statistically significant reduction of symptoms, as assessed by PANSS total score, starting at Week

“In addition, we are looking forward to the data read-out from the ADX71149 epilepsy Phase 2 study in

August 2022 "We are proud to announce that SYnAbs is now officially accredited as a Research Tax Credit I would like to take this opportunity to thank all our French partners who trust us in the generation

August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on Jonah Comstock delves into what makes this team-up tick. support third party research, but the group also does its own research into promising therapy areas, working with partners who have a good idea but don’t have all the necessary tools to drive it forward."

The reserved indications, where Addex retains exclusive rights to develop its own independent GABAB PAM

Two β3 -AR agonists are used clinically: mirabegron 1 and vibegron 2, which are indicated for overactive Out of 35 tested compounds, 4 compounds were active in CHO-K1 cells expressing the human β3 -AR, and 8 compounds were active in CHO-K1 cells expressing the mouse β3 -AR."

Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well

August 2022 "WELCOME 4GPCRnet meeting bringing together four of the biggest GPCR networks in Europe for ERNEST plus DFG-funded SFB1423 and FOR2372) have joined forces to organize an international meeting, which We aim to connect renowned international experts of the field with early career ‘rising stars’. The event will take place in the heart of Leipzig, which offers a colorful mixture of culture and vivid

2022 "Abstract Chemokines such as stromal derived factor 1 and their G protein coupled receptors are well-known In support of this conclusion, we have shown that ACKR3 is unable to signal through any of the known We also synthesized a series of small molecule ligands which acted as selective agonists for ACKR3 as atypical chemokine receptor 3 (ACKR3), which signals atypically. This work will help to better understand the unique signaling roles of ACKR3."

We aimed to exploit other mamba venoms to enlarge the V2R-Kunitz peptide family and gain insight into MQs were produced by solid-phase peptide synthesis and characterized in vitro by binding and functional Key results: Eight additional MQs were identified with nanomolar affinities for the V2R, all antagonists Sequence comparison between active and non-active V2R Kunitz peptides highlighted five positions, among which We finally determined that eight positions, part of these two loops, interact with the V2R.

In this study, we report the discovery of a novel lead compound for S1R binding, based on the thiazolidine We have explored hydrophobic groups of different sizes on both sides of the five-membered ring scaffold

the human PTH1R) can lead to differences in receptor-binding and signaling potencies for such ligands when To overcome this potential uncertainty, we used a homologous recombination-based knockin (KI) approach to generate a mouse (in-host strain C57Bl/6N) in which complementary DNA encoding the human PTH1R replaces The resulting homozygous hPTH1R-KI (humanized) mice were healthy over at least 10 generations and showed

promotion of Senior Vice President, Head of Research, Peter McNamara , PhD, to Chief Scientific Officer as well as the appointments of Barry Rubenstein as Senior Vice President, People and Culture and Washington

"We recently hosted our annual Scientific Advisory Board (SAB) summit at our site within Granta Park. It was great to bring everyone together and also welcome new member John Parkinson ."

July 2022 "Today we are celebrating ten years of Exscientia ! We have achieved a great deal in the last decade, such as the first-ever AI-designed drug candidates foundations, and the establishment of a global company with locations in the UK, U.S., Austria, and Japan which We’re excited about delivering the next ten years of Exscientia and advancing AI to design better drugs

the form of 550,000 American Depositary Shares (“ADSs”) at a gross purchase price of $1.70 per ADS, which up to 11,700,000 shares in the form of 1,950,000 ADSs (the “Unregistered Pre-Funded Warrants”) at a funded amount of $1.69 with $0.01 payable on exercise as well as unregistered warrants to purchase up to 15,000,000 shares in the form of 2,500,000 ADSs (the “Unregistered Warrants” and together with the “Unregistered Pre-Funded Warrants”, the “Warrants”) in a concurrent private placement.

immunotherapy candidate into clinical trials " HTL0039732 is a novel EP4 antagonist with potential to treat a wide Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR1-focused structure-based drug design (SBDD) and development, an d Cancer Research UK , the world